{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:23:03Z","timestamp":1791973383837,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.clinthera.2007.08.006","type":"journal-article","created":{"date-parts":[[2007,10,4]],"date-time":"2007-10-04T14:45:34Z","timestamp":1191509134000},"page":"1645-1654","source":"Crossref","is-referenced-by-count":79,"title":["Effect of Miglustat on Bone Disease in Adults with Type 1 Gaucher Disease: A Pooled Analysis of Three Multinational, Open-Label Studies"],"prefix":"10.1016","volume":"29","author":[{"given":"Gregory M.","family":"Pastores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Elstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hreb\u00edcek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2007.08.006_bib1","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2007.08.006_bib2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0950-3536(97)80033-9","article-title":"Gaucher's disease: Clinical features and natural history","volume":"10","author":"Cox","year":"1997","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.clinthera.2007.08.006_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","article-title":"Quality of-life related to type 1 Gaucher disease: Spanish experience","volume":"14","author":"Giraldo","year":"2005","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2007.08.006_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11926-000-0059-x","article-title":"Bone and joint complications related to Gaucher disease","volume":"2","author":"Pastores","year":"2000","journal-title":"Curr Rheumatol Red"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.08.006_bib5","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","article-title":"Skeletal aspects of Gaucher disease: A review","volume":"75","author":"Wenstrup","year":"2002","journal-title":"Br J Radiol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.08.006_bib6","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1259\/bjr.75.suppl_1.750013","article-title":"Imaging and quantifying skeletal involvement in Gaucher disease","volume":"75","author":"Maas","year":"2002","journal-title":"BrJ Radiol"},{"key":"10.1016\/j.clinthera.2007.08.006_bib7","first-page":"961","article-title":"et al","volume":"179","author":"Maas","year":"2002","journal-title":"Quantification of skeletal involvement in adults with type I Gaucher's disease: Fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol"},{"key":"10.1016\/j.clinthera.2007.08.006_bib8","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/jbmr.5650111125","article-title":"Bone density in type 1 Gaucher disease","volume":"11","author":"Pastores","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.08.006_bib9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev.genom.4.070802.110415","article-title":"Enzyme therapy for lysosomal storage disease: Principles, practice, and prospects","volume":"4","author":"Grabowski","year":"2003","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.clinthera.2007.08.006_bib10","first-page":"408","article-title":"Grabowski GA","volume":"82","author":"Pastores","year":"1993","journal-title":"Enzyme therapy in Gaucher disease type 1: Dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.08.006_bib11","first-page":"A25","article-title":"et al","volume":"75","author":"Poll","year":"2002","journal-title":"Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol"},{"key":"10.1016\/j.clinthera.2007.08.006_bib12","first-page":"112","article-title":"et al","volume":"113","author":"Weinreb","year":"2002","journal-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry. Amy Med"},{"key":"10.1016\/j.clinthera.2007.08.006_bib13","first-page":"830","article-title":"et al","volume":"108","author":"de Fost","year":"2006","journal-title":"Superior effects of high-dose enzyme replacement therapy in type I Gaucher disease on bone marrow involvement and chitotriosidase levels: A 2-center retrospective analysis. Blood"},{"key":"10.1016\/j.clinthera.2007.08.006_bib14","first-page":"597","article-title":"et al","volume":"22","author":"Lebel","year":"2004","journal-title":"Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab"},{"key":"10.1016\/j.clinthera.2007.08.006_bib15","first-page":"209","article-title":"et al","volume":"69","author":"Mankin","year":"2006","journal-title":"A questionnaire study for 128 patients with Gaucher disease. Clin Genet"},{"key":"10.1016\/j.clinthera.2007.08.006_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/00498250601094543","article-title":"The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat","volume":"37","author":"Treiber","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2007.08.006_bib17","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1016\/S0021-9258(17)37202-2","article-title":"N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis","volume":"269","author":"Platt","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2007.08.006_bib18","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2007.08.006_bib19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinthera.2007.08.006_bib20","first-page":"127","article-title":"et al","volume":"28","author":"Heitner","year":"2002","journal-title":"Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease [published correction appears in Blood Cells Mol Dis. 2003;28:301]. Blood Cells Mol Dis"},{"key":"10.1016\/j.clinthera.2007.08.006_bib21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1098\/rstb.2003.1272","article-title":"Elstein D","volume":"358","author":"Zimran","year":"2003","journal-title":"Gaucher disease and the clinical experience with substrate reduction therapy. Philos Tram R Soc Lond B Biol Sci"},{"key":"10.1016\/j.clinthera.2007.08.006_bib22","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","article-title":"An open-label, noncomparative study of miglustat in type I Gaucher disease: Efficacy and tolerability over 24 months of treatment","volume":"27","author":"Pastores","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2007.08.006_bib23","first-page":"152","article-title":"et al","volume":"20","author":"Tucker","year":"2005","journal-title":"Low plasma vitamin B12 is associated with lower BMD: The Framingham Osteoporosis Study.J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.08.006_bib24","first-page":"21","article-title":"Enhanced differentiation of osteoclasts from mononuclear precursors in patients with Gaucher disease","volume":"29","author":"Hughes","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinthera.2007.08.006_bib25","first-page":"19","article-title":"et al","volume":"90","author":"Allen","year":"1997","journal-title":"Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: Increased release of interleukin-6 and interleukin-10. QJM"},{"key":"10.1016\/j.clinthera.2007.08.006_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s774-002-8444-1","article-title":"Bone ultrasonometry, bone density, and turnover markers in type 1 Gaucher disease","volume":"20","author":"Fiore","year":"2002","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.clinthera.2007.08.006_bib27","first-page":"185","article-title":"et al","volume":"72","author":"Ciana","year":"2003","journal-title":"Bone markers alterations in patients with type I Gaucher disease. CalcifTissue Int"},{"key":"10.1016\/j.clinthera.2007.08.006_bib28","first-page":"119","article-title":"et al","volume":"22","author":"Wenstrup","year":"2007","journal-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease, J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.08.006_bib29","first-page":"723","article-title":"et al","volume":"28","author":"Ciana","year":"2005","journal-title":"Gaucher disease and bone: Laboratory and skeletal mineral densityvariations during a long period of enzyme replacement therapy. J Inherit Metab Dis"},{"key":"10.1016\/j.clinthera.2007.08.006_bib30","first-page":"288","article-title":"et al","volume":"28","author":"Schiffmann","year":"2002","journal-title":"Decrease bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis"},{"key":"10.1016\/j.clinthera.2007.08.006_bib31","first-page":"273","article-title":"et al","volume":"70","author":"Rudzki","year":"2003","journal-title":"Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease\u2014a histological study. Eur J Haematol"},{"key":"10.1016\/j.clinthera.2007.08.006_bib32","first-page":"205","article-title":"Weinreb NJ","volume":"71","author":"Charrow","year":"2007","journal-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet"},{"key":"10.1016\/j.clinthera.2007.08.006_bib33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF03401556","article-title":"Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages","volume":"1","author":"Beutler","year":"1995","journal-title":"Mol Med"},{"key":"10.1016\/j.clinthera.2007.08.006_bib34","first-page":"195","article-title":"et al","volume":"100","author":"Fukumoto","year":"2006","journal-title":"Current topics in pharmacological research on bone metabolism: Osteoclast differentiation regulated by glycosphingolipids. J Pharmacol Sci"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180700241X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180700241X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T05:26:44Z","timestamp":1629869204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929180700241X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S014929180700241X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2007.08.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}